


Assessing Cardiac Masses with Cardiac Magnetic Resonance Imaging

Faisal Nabi, MD, FACC

September 12, 2022



Differential Diagnosis of a Cardiac Mass



Cardiac Mass
on Echo

Artifact/
Normal Variant

Thrombus

Vegetation

Tumor

Echocardiography:


Primary Modality for Imaging Intracardiac Disease

Advantages


- Readily available
- Identifies morphology, location
- Doppler identifies altered hemodynamics
- Many cases, characteristic features permit a differential diagnosis

Disadvantages

- Operator dependent
- Acoustic window restrictions (restricted FOV)
 - Limited imaging of the right heart
 - Mediastinal/extra-cardiac structures
 - Obesity / COPD
- Poor soft tissue characterization
- TEE is invasive



Advanced Imaging of Cardiac Masses




Modality	Echocardiography	Cardiac MRI	Cardiac CTA
Field of view	++	+++	+++
Tissue characterization	+	+++	++
Temporal resolution	+++	++	+
Perfusion assessment	++	+++	+
Spatial resolution	+	+++	+++

CMR Provides Incremental Value

Accurate description of:

- Tumor anatomy (shape, size, location)
- Tumor extension
- Vascularity
- Tissue contrast (fat, thrombus, fluid, iron)



Added value:

- 1) Detail its relationship to other cardiac and extra-cardiac structures
- 2) Identify & contribute to differential diagnosis of a cardiac mass
- 3) Plan therapy (eg. surgery or chemotherapy)
- 4) Monitor tumor regression after therapy with serial studies

2019 Appropriate Use Criteria for Multimodality Imaging

Indication	TTE (With or Without 3D; With Contrast as Needed)	TEE (With or Without 3D)	Stress Echo*	Strain/Strain Rate Imaging by Speckle or Tissue Doppler	F-18 FDG PET	Tc-99m PYP	MPI (SPECT/PET)	CMR	CT†	ANG	RVG
Other											
40. Suspected pericardial diseases	9 (A)	4 (M)	1 (R)	5 (M)	1 (R)	1 (R)	1 (R)	7 (A)	7 (A)	1 (R)	1 (R)
41. Initial evaluation of cardiac mass, suspected tumor or thrombus, or potential cardiac source of emboli	9 (A)	7 (A)	1 (R)	1 (R)	1 (R)	1 (R)	1 (R)	7 (A)	7 (A)	1 (R)	1 (R)

CMR Imaging Protocol: Cardiac Masses

Functional Imaging

Structural Imaging

Axial/Coronal
Sagittal Stack
(bright/dark
blood)

SSFP Cine
Imaging

T1 / T2 FSE
 \pm fat sup
 \pm T2*

Dynamic
First Pass
Rest
perfusion




Late
Gadolinium
Enhancement

Long T1
Imaging

Gd
Contrast



CMR Imaging Protocol: Functional Imaging with Cine SSFP




- Standard cine imaging of the heart from base to apex in both short- and long-axis views
- Targeted non-standard imaging planes for optimal visualization
- Value:
 - Confirm location, size & morphology
 - Assess mobility
 - Assess physiological impact
 - Assess tumor extension or involvement of the pericardium, mediastinum, lungs, lymph nodes and vascular bed

CMR Imaging Protocol: Structural Assessment

Superior Ability to Discriminate Tissue Characteristics



Pre-Contrast Images

- **T1 Weighted sequences**
 - Fat
 - Acute blood
- **T2 Weighted sequences**
 - Edema (water)
- **T2* sequence**
 - Iron / blood breakdown products



Contrast Enhanced Images

- **Dynamic first pass rest perfusion**
 - Vascularity
- **Delayed hyperenhancement**
 - Fibrosis / necrosis / inflammation
- **Long TI Imaging**
 - Thrombus






Contribute to differential diagnosis of a cardiac mass

CMR Imaging Protocol: Structural Assessment

Superior Ability to Discriminate Tissue Characteristics

Pre-Contrast Images

- **T1 Weighted**
 - Fat
 - Acute blood
- **T2 Weighted**
 - Edema (water)
- **T2* Sequence**
 - Iron / blood breakdown products







CMR Imaging Protocol: Structural Assessment



Superior Ability to Discriminate Tissue Characteristics

Contrast Enhanced Images

- Dynamic Rest Perfusion
 - Vascularity
- Delayed hyperenhancement
 - Fibrosis/necrosis/inflamm
- Long T1 Imaging
 - Thrombus



Contribute to differential diagnosis of cardiac mass

Step Wise Cardiac Mass Evaluation

STEP 1

Cardiac mass

```
graph TD; A[Cardiac mass] --> B[True Mass]; A --> C[Pseudo Mass]
```

STEP 1


True Mass

Pseudo
Mass

Tumor vs Pseudo-Mass

Case 1

74M with CVA found to have RA mass




Prominent christa terminalis



Tumor vs Pseudo-Mass

Case 2

51F CAD admitted with epigastric pain




Hiatal hernia



Normal Structures that can be Mistaken for an Abnormal Cardiac Mass



Left atrium	<ul style="list-style-type: none"> Dilated coronary sinus (persistent left superior vena cava) Raphe between left superior pulmonary vein and LA appendage Atrial suture line after cardiac transplant Beam-width artifact from calcified aortic valve, aortic valve prosthesis, or other echogenic target adjacent to the atrium Interatrial septal aneurysm
Right atrium	<ul style="list-style-type: none"> Crista terminalis Chiari network (Eustachian valve remnants) Lipomatous hypertrophy of the interatrial septum Trabeculation of RA appendage Atrial suture line after cardiac transplant Pacer wire, Swan-Ganz catheter, or central venous line
Left ventricle	<ul style="list-style-type: none"> Papillary muscles LV web (aberrant chordae) Prominent apical trabeculations Prominent mitral annular calcification
Right ventricle	<ul style="list-style-type: none"> Moderator band Papillary muscles Swan-Ganz catheter or pacer wire
Aortic valve	<ul style="list-style-type: none"> Nodules of Arantius Lambl excrescences Base of valve leaflet seen <i>en face</i> in diastole
Mitral valve	<ul style="list-style-type: none"> Redundant chordae Myxomatous mitral valve tissue
Pulmonary artery	<ul style="list-style-type: none"> LA appendage (just caudal to pulmonary artery)
Pericardium	<ul style="list-style-type: none"> Epicardial adipose tissue Fibrinous debris in a chronic organized pericardial effusion

Step Wise Cardiac Mass Evaluation



Tumor vs Pseudo-tumor

Case3




Lipomatous
hypertrophy
of the IAS

T1 Spin Echo




T2 with FS



Tumor vs Pseudo-tumor

Case 4





Pericardial
Cyst

Tumor vs Pseudotumor

Case 5


A 77 year-old asymptomatic female with a history of a very recent 2V-CABG referred from OSH for surgical removal of a new LA mass found on a post-op TTE




Tumor vs Pseudotumor

Case 5


T1




T2 with
fat sat



First
pass
rest
perfusion




LGE




Case 5

Non-contrast Cardiac CT



TTE – Apical 4 CH





Caseating Mitral Annular Calcification

Thrombus vs Tumor



Case 1

52M DM, MVR'09, chronic afib on anti-coagulation, nl EF, admitted with DHF




Case1

T1/T2




Rest Perfusion



Case1

Long TI Imaging



Thrombus

-confirmed on surgery-

CMR imaging enables thrombus to be detected based on intrinsic tissue characteristics related to avascular tissue composition


Thrombus vs Tumor

Case2

Cine-CMR


Contrast-CMR with Long T1

Baseline



Cine-CMR

After
anti-coagulation



LV
Thrombus

CE- MRI Provides High Sensitivity & Specificity for LV Thrombus

- 160 patients with IHD had TTE/TEE/CMR within 30d of LV reconstruction surgery and pathological confirmation of presence or absence of LV thrombus
- Left ventricular thrombus was present in 29%





Table III. Sensitivity and specificity for subgroup with all 3 imaging modalities


	Total (n)	MRI	TTE	TEE
Sensitivity	48	88% (79%-97%)	23% (11%-35%)	40% (26%-54%)
Specificity	112	99% (97%-100%)	96% (92%-99.6%)	96% (92%-99.6%)

Diagnostic Performance of Routine Imaging for LV Thrombus

- Mixed cohort of heart failure and post-MI patients (n=121)
- Calculated using DE-CMR as the standard for LV thrombus (20%)

	Sensitivity	Specificity	Accuracy	Positive Predictive Value	Negative Predictive Value
Noncontrast Echo	33%	94%	82%	57%	85%
Contrast Echo	61%	99%	92%	93%	91%
Cine-CMR	79%	99%	95%	95%	95%

- Cine-CMR more sensitive than echo
- Sensitivity of Echo & CMR is significantly improved with IV contrast
- Thrombi missed by echo were more likely to be:
 - small in size
 - mural in shape



Hypointensity with Long T1 Has the Highest Accuracy for Thrombus

116 patients: 84 thrombi, 17 benign tumors, & 25 malignant tumors



TABLE 3 Accuracy of CMR Features for the Diagnosis of Thrombus (Versus Tumor)

	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Accuracy (%)
Pre-contrast visualization (-)	23	100	100	39	48
Diameter <2.4 cm	84	78	88	72	82
Area <4.1 cm ²	89	80	89	79	86
Homogeneous (+)	99	54	81	96	84
Motility (-)	87	33	72	56	69
T2w-TSE hyperintensity (-)	58	85	81	65	71
FPP (-)	96	70	81	93	85
LGE (-)	95	71	86	88	87
Typical T1 scout pattern*	94	98	98	91	95
T1 time ≥422 ms	67	80	77	71	73




CMR Useful in Identifying Structural Risk Factors That Predispose to LV Thrombus

784 pts with LVEF <50%




CMR also identifies structural risk factors for LV thrombus, including infarct size/distribution and contractile dysfunction

Step-Wise Cardiac Mass Evaluation




Tumors are Hyperintense on T2, FPP, LGE, & Long TI

116 patients: 84 thrombi, 17 benign tumors, & 25 malignant tumors



Contrast Uptake = Tumor


Tumor (+) FPP




(+) LGE
(+) Long TI




Thrombus (-) FPP




(-) LGE
(-) Long TI




Benign vs Malignant



Panel 1: Myxoma



Panel 2: Sarcoma



LGE Showed Moderate Ability to Differentiate Benign from Malignant

116 patients: 84 thrombi, 17 benign tumors, & 25 malignant tumors

TABLE 4 Accuracy of CMR Features for the Diagnosis of Malignant (Versus Benign) Tumor

	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Accuracy (%)
Diameter ≥ 4.2 cm	52	100	100	61	73
Area ≥ 13.4 cm ²	48	100	100	57	69
FPP (+)	84	53	75	67	73
LGE (+)	92	59	78	83	79

Overlap in CMR tissue characteristics may require tissue diagnosis to aid in final determination

Non-invasive Etiology of a Mass Requires Integrated Approach

Clinical history



Signs and symptoms




Biochemical/tumor markers



Results of all cardiovascular imaging
(including location and tissue characterization)

Range of Cardiac Tumors: Primary and Secondary



Benign vs. Malignant: Characteristics


Benign Tumor

- Small size
- Involvement of the left side of the heart
- Solitary tumor
- Smooth margins
- Intracameral
- Narrow stalk


Malignant tumor

- >5cm in size
- Involvement of the right heart
- Multiple tumors
- Irregular margins
- Broad base
- Intramural
- Invasion of the surrounding tissue
- Pleural or pericardial effusion

BENIGN TUMORS OF THE HEART





MALIGNANT TUMORS OF THE HEART




Characteristics of Malignant Cardiac Masses

Tumor Characteristics

- Large size—especially if >5 cm
- Irregular, ill-defined borders
- Direct invasion through tissue planes
- Most cardiac tumors involving the right heart are suspicious for malignancy
- Pericardial or pleural involvement—effusions and nodular masses
- Multiple lesions



Location Helps with Etiology




Non-invasive Tissue Characterication Helps with Etiology

Cardic Mass	T1 Weighted	T2 Weighted	Post Contrast
Myxoma	Isointense, heterogeneous	Hyperintense, heterogeneous	Heterogeneous enhancement
Papillary fibroelastoma	Isointense	Hyperintense	Hyperintense
Rhabdomyoma	Iso- or hyperintense	Slightly hyperintense	Hyperintense
Fibroma	Iso- or hyperintense	Hypointense	Hyperintense
Hemangioma	Isointense	Hyperintense, heterogeneous	Hyperintense or heterogeneous
Paraganglioma	Iso- or hypointense	Hyperintense	Hyperintense
Intravenous leiomyomatosis	Isointense	Isointense	Heterogeneous
Bronchogenic cyst	Hypointense	Hyperintense	None
Angiosarcoma	Isointense, with hyperintense areas	Iso- or hyperintense	Hyperintense
Undifferentiated sarcoma	Isointense	Isointense	Nonspecific
Rhabdomyosarcoma	Isointense	Isointense, heterogeneous	Central nonenhancing areas
Osteosarcoma	Hyperintense	Hyperintense	Nonspecific
Malignant fibrous histiocytoma	Isointense	Hyperintense, heterogeneous	Nonspecific
Leiomyosarcoma	Isointense	Hyperintense	Nonspecific
Fibrosarcoma	Isointense, heterogeneous	Hyperintense	Central nonenhancing areas
Lymphoma	Hypo- or isointense	Hyperintense	Variable


Malignant Tumors Demonstrate More Contrast Uptake

116 patients: 84 thrombi, 17 benign tumors, & 25 malignant tumors




Malignant tumors were larger and more frequently exhibited FPP and LGE

CMR Valuable Method for Differentiating Malignant from Benign Cardiac Tumors






Secondary: Metastatic


69M known melanoma with RA mass by TTE



Multiple areas of
delayed hyperenhancement




Liver mets




Metastatic Melanoma

Primary Benign: Myxoma



Myxoma





- Most common type of primary benign cardiac tumors
- Occur predominantly in adulthood; avg ~50yrs
- Always intracavitary, most commonly located in the LA (75%)
 - 20% RA, 5% ventricular origin
- Usually attached to IAS near the fossa ovalis
- Well defined, lobular or oval, and often pedunculated; may be mobile
- May contain cysts, regions of necrosis, fibrosis, hemorrhage and calcification
- Asymptomatic if small; otherwise present with mass effect, embolization or constitutional symptoms (IL-6)
- CMR findings: Heterogeneous mass with heterogeneous enhancement

Primary Benign


Mitral valve

Tricuspid valve

Papillary
fibroelastoma




Perfusion



DE

Intense contrast uptake




Papillary Fibroelastoma



- Account for 75% of valvular neoplasms
- Benign, small (<1.5cm), high mobile, valvular mass
 - Rarely associated with valvular dysfunction
- *Avascular*, endocardial papillomas
 - Similar to Lambl's excrescences (histologically, cardiac valve predilection). Differ in that they tend to be larger in size and away from the site of valve closure
- Usually detected incidentally
- Rarely require excision except embolic symptoms
 - Larger, highly mobile, left sided tumors
- CMR findings: Valvular mass with contrast uptake





Primary Benign



T1




T2



Cine FISP

Fibroma

Perfusion




Delayed HE

Fibromas


- Congenital in origin; occur in children; young adults
- Solitary, *avascular* intramural masses within ventricular myocardium
 - Discrete focal mass of collagen and fibroblasts
- Presentation: Arrhythmias, syncope, CP, HF
- CMR features:
 - Reduced signal on T2-weighted imaging (due to their limited water content)
 - Very high signal intensity on delayed enhancement imaging (due to their high collagen content)

D. Fibroma



Copyright © 2005 by Elsevier Inc.


62F with frequent palpitations and frequent syncope




T1



T2 with
fat sat




Lipoma




Lipomas


- Benign, avascular
- Well defined, homogenous, encapsulated tumors containing neoplastic adipose cells
- Majority arise from the epicardial surface
 - Subendocardial lipomas less common
- Rare, more often present as lipomatous hypertrophy of the interatrial septum
- Presentation: Asymptomatic, arrhythmias, obstruction





Cine



Cine




Perfusion



T1 weighted



T2 weighted




Post contrast

Paragangliomas

- Originate from neuroendocrine cells
- Typically present with symptoms of catecholamine excess (e.g., hypertension, tachyarrhythmias or heart failure)
- Usually originate in the atria, along the atrioventricular sulcus or at the root of the great vessels.
- CMR Imaging features:
 - high signal on T2-weighted imaging
 - heterogeneous delayed hyperenhancement
 - high vascularity on perfusion imaging

2 patients presenting with SOB
FPP


Cine









FPP



DE




Primary Malignant: Sarcoma



Sarcomas

- Comprise 95% of primary malignant cardiac tumors
 - Angiosarcoma is the most common form (~40%)
- Poor prognosis
 - Rapid progression, widespread infiltration, obstruction, metastasis
- Angiosarcomas have predilection for the RA (>90%)
 - Unlike other sarcomas
- As the imaging features of different forms of sarcomas are similar, specific differentiation can only be made by histology

More than One Test May be Required



Take Home Points

- CMR can identify with high specificity cardiac masses which do not require excision:
 - Pseudo-masses
 - Thrombus
 - Lipoma / lipomatous hypertrophy
 - Water based Cysts
- Can generate a differential diagnosis with an integration of history, symptoms, biomarkers and imaging findings
- Most cardiac tumors will require tissue diagnosis to aid in determination of treatment plan